Back to Research

Organization profile

NovaGo Therapeutics

NovaGo Therapeutics is a Swiss biotechnology company that develops regenerative antibody therapies to repair traumatic injuries of the central nervous system. Its lead program focuses on blocking Nogo-A, a potent nerve growth inhibitor, to stimulate axon regeneration and restore functional movement in patients with acute spinal cord injury.

Schlieren, SwitzerlandFounded 2015

Overview

1. Executive Summary (Confidence: High)

Founded in 2015 as a spin-off from the University of Zurich, NovaGo Therapeutics is a pioneer in the field of neuro-regeneration. The company’s core strategy revolves around its lead drug candidate, NG004, a human monoclonal antibody currently in a First-in-human (FIH) Phase 1b trial known as "SPROUT". NovaGo addresses a critical unmet medical need: the restoration of motor and sensory function after spinal cord injury (SCI), for which no effective restorative therapy currently exists. By leveraging a strategic partnership with Neurimmune AG for antibody discovery, NovaGo has developed a high-affinity therapy that targets the biological "brakes" on nerve growth, aiming to transform SCI from a permanent disability into a treatable condition.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.